WHO: Christopher L. Amling, M.D., AUA Public Media Committee David Penson, M.D., University of Southern California, Norris Cancer Center

WHAT: Data on Provenge, a new therapeutic prostate cancer vaccine, was presented during the Plenary Session. David Penson, M.D. met with interested members of the media in advance of the presentation to provide background and perspective on this new therapy for metastatic prostate cancer.

###

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 15,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients, including UrologyHealth, an award-winning on-line patient education resource, and the American Urological Association Foundation, Inc., formerly AFUD.

Contact: Wendy Isett
American Urological Association

View drug information on Provenge.